Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$3.93
-1.3%
$5.05
$3.42
$7.20
$222.82M1.821.56 million shs1.26 million shs
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$3.65
-1.0%
$4.06
$3.21
$8.06
$872.10M0.594.51 million shs1.67 million shs
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$29.07
-2.4%
$28.20
$16.28
$38.93
$816.94M0.42188,864 shs176,424 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$12.81
-0.1%
$12.12
$8.21
$17.70
$891.28M1.17549,389 shs122,860 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+1.79%-32.31%-27.64%-9.75%-21.81%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+1.38%+3.66%-7.30%-26.98%-41.12%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-2.30%+2.83%+5.72%+14.14%+64.26%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+2.81%+4.74%+11.09%+3.81%+52.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2495 of 5 stars
0.02.00.00.01.00.80.6
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.1902 of 5 stars
3.51.00.04.43.32.50.6
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
1.3242 of 5 stars
3.61.00.00.01.40.80.0
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.8487 of 5 stars
3.50.00.00.02.23.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.89198.73% Upside
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
3.17
Buy$46.6060.30% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0063.96% Upside

Current Analyst Ratings Breakdown

Latest ACB, ARDX, ZYME, and LENZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/8/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$11.00
4/16/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/14/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M0.90$0.61 per share6.40$7.78 per share0.51
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M2.61N/AN/A$0.73 per share4.99
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/A$7.42 per shareN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M9.54N/AN/A$6.63 per share1.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1136.048.93N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A11.76N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$49.77M-$1.77N/AN/AN/AN/A-23.74%-22.65%8/13/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)

Latest ACB, ARDX, ZYME, and LENZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
5/7/2025Q1 2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.55-$0.53+$0.02-$0.53N/AN/A
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.04
4.12
3.81
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/A
23.09
23.09
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
54.32%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
6.90%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,07356.21 million56.21 millionOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million227.77 millionOptionable
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
11028.15 million26.20 millionN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.58 million67.56 millionOptionable

Recent News About These Companies

Zymeworks’ zanidatamab approved in China

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$3.94 -0.05 (-1.13%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$3.64 -0.04 (-0.95%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

LENZ Therapeutics stock logo

LENZ Therapeutics NASDAQ:LENZ

$29.14 -0.64 (-2.14%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$12.80 -0.02 (-0.12%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.